Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00720304 · OUTCOME

Percent of Participants With Distant Metastasis-free Survival

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck · Source last updated 2024-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent
Interval / dispersion
Not reported
Time frame
At 3 years

What was measured

Percent of participants with distant metastasis-free survival

Analysis population: Participants enrolled in study

Groups in this outcome

Oral Erlotinib Hydrochloride

docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Oral Erlotinib Hydrochloride43

Reported measurements

Source class 1
Values in percent · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Oral Erlotinib Hydrochloride83.7Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        83.7
denoms
  1. counts
    1. group Id
      OG000
      value
      43
    units
    Participants
description
Percent of participants with distant metastasis-free survival
groups
  1. description
    docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
    id
    OG000
    title
    Oral Erlotinib Hydrochloride
param Type
NUMBER
population Description
Participants enrolled in study
reporting Status
POSTED
time Frame
At 3 years
title
Percent of Participants With Distant Metastasis-free Survival
type
SECONDARY
unit Of Measure
percent

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice